{"title":"不同外用双氯芬酸制剂治疗膝骨关节炎的疗效和安全性:短期和长期治疗比较的荟萃分析。","authors":"Zhi-Rong Chen, Bing-Keng Chen, Peng Li, Kai Feng","doi":"10.1186/s12891-025-08465-7","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>This meta-analysis evaluates the efficacy and safety of various topical dosage forms of diclofenac (gel, solution, and patch) for the treatment of knee osteoarthritis.</p><p><strong>Methods: </strong>A comprehensive literature search was conducted in PubMed, Embase, Cochrane Library, and Web of Science for randomized controlled trials evaluating topical diclofenac formulations in knee osteoarthritis patients. Data on pain relief, functional outcomes, and adverse events were extracted. The primary outcomes were pain and function scores at different follow-up intervals (1-2 weeks, 3-6 weeks, 8-12 weeks), and safety outcomes.</p><p><strong>Results: </strong>A total of 12 randomized controlled trials (RCTs) were included in the analysis. Diclofenac gel, solution, and patch were all shown to significantly alleviate pain and improve function in patients with knee osteoarthritis. At 1-2 weeks, the diclofenac patch delivered the most pronounced short-term pain relief (SMD: -0.64; 95% CI: -0.90 to -0.39), while the gel and solution demonstrated sustained efficacy over the mid-term (3-6 weeks) and long-term (8-12 weeks). whereas skin-related adverse events, systemic side effects and withdrawal rates remained low across all formulations. The overall quality of evidence was assessed as moderate to high, reinforcing the robustness of the findings.</p><p><strong>Conclusions: </strong>Topical diclofenac formulations (gel, solution, patch) significantly improve pain and function in knee osteoarthritis compared to placebo. All formulations were well-tolerated, with no significant increase in adverse events. These findings support the use of topical diclofenac for short-term pain relief and functional improvement in KOA patients.</p>","PeriodicalId":9189,"journal":{"name":"BMC Musculoskeletal Disorders","volume":"26 1","pages":"230"},"PeriodicalIF":2.4000,"publicationDate":"2025-03-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11892197/pdf/","citationCount":"0","resultStr":"{\"title\":\"Efficacy and safety of different topical diclofenac formulations for the treatment of knee osteoarthritis: a meta-analysis of short-term and long-term treatment comparisons.\",\"authors\":\"Zhi-Rong Chen, Bing-Keng Chen, Peng Li, Kai Feng\",\"doi\":\"10.1186/s12891-025-08465-7\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objective: </strong>This meta-analysis evaluates the efficacy and safety of various topical dosage forms of diclofenac (gel, solution, and patch) for the treatment of knee osteoarthritis.</p><p><strong>Methods: </strong>A comprehensive literature search was conducted in PubMed, Embase, Cochrane Library, and Web of Science for randomized controlled trials evaluating topical diclofenac formulations in knee osteoarthritis patients. Data on pain relief, functional outcomes, and adverse events were extracted. The primary outcomes were pain and function scores at different follow-up intervals (1-2 weeks, 3-6 weeks, 8-12 weeks), and safety outcomes.</p><p><strong>Results: </strong>A total of 12 randomized controlled trials (RCTs) were included in the analysis. Diclofenac gel, solution, and patch were all shown to significantly alleviate pain and improve function in patients with knee osteoarthritis. At 1-2 weeks, the diclofenac patch delivered the most pronounced short-term pain relief (SMD: -0.64; 95% CI: -0.90 to -0.39), while the gel and solution demonstrated sustained efficacy over the mid-term (3-6 weeks) and long-term (8-12 weeks). whereas skin-related adverse events, systemic side effects and withdrawal rates remained low across all formulations. The overall quality of evidence was assessed as moderate to high, reinforcing the robustness of the findings.</p><p><strong>Conclusions: </strong>Topical diclofenac formulations (gel, solution, patch) significantly improve pain and function in knee osteoarthritis compared to placebo. All formulations were well-tolerated, with no significant increase in adverse events. These findings support the use of topical diclofenac for short-term pain relief and functional improvement in KOA patients.</p>\",\"PeriodicalId\":9189,\"journal\":{\"name\":\"BMC Musculoskeletal Disorders\",\"volume\":\"26 1\",\"pages\":\"230\"},\"PeriodicalIF\":2.4000,\"publicationDate\":\"2025-03-10\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11892197/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"BMC Musculoskeletal Disorders\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1186/s12891-025-08465-7\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"ORTHOPEDICS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"BMC Musculoskeletal Disorders","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s12891-025-08465-7","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ORTHOPEDICS","Score":null,"Total":0}
引用次数: 0
摘要
目的:本荟萃分析评估了不同外用剂量形式的双氯芬酸(凝胶、溶液和贴剂)治疗膝骨关节炎的疗效和安全性。方法:在PubMed、Embase、Cochrane Library和Web of Science中进行全面的文献检索,以评估双氯芬酸外用制剂对膝关节骨关节炎患者的疗效。提取疼痛缓解、功能结局和不良事件的数据。主要结局是不同随访时间(1-2周、3-6周、8-12周)的疼痛和功能评分,以及安全性结局。结果:共纳入12项随机对照试验(rct)。双氯芬酸凝胶、溶液和贴片均能显著缓解膝关节骨关节炎患者的疼痛和改善功能。在1-2周时,双氯芬酸贴片提供了最明显的短期疼痛缓解(SMD: -0.64;95% CI: -0.90至-0.39),而凝胶和溶液在中期(3-6周)和长期(8-12周)表现出持续的疗效。然而,与皮肤相关的不良事件、全身副作用和停药率在所有配方中仍然很低。证据的总体质量被评估为中等到高,加强了研究结果的稳健性。结论:与安慰剂相比,局部双氯芬酸制剂(凝胶、溶液、贴片)可显著改善膝关节骨关节炎的疼痛和功能。所有制剂耐受性良好,不良事件无显著增加。这些发现支持局部双氯芬酸用于KOA患者的短期疼痛缓解和功能改善。
Efficacy and safety of different topical diclofenac formulations for the treatment of knee osteoarthritis: a meta-analysis of short-term and long-term treatment comparisons.
Objective: This meta-analysis evaluates the efficacy and safety of various topical dosage forms of diclofenac (gel, solution, and patch) for the treatment of knee osteoarthritis.
Methods: A comprehensive literature search was conducted in PubMed, Embase, Cochrane Library, and Web of Science for randomized controlled trials evaluating topical diclofenac formulations in knee osteoarthritis patients. Data on pain relief, functional outcomes, and adverse events were extracted. The primary outcomes were pain and function scores at different follow-up intervals (1-2 weeks, 3-6 weeks, 8-12 weeks), and safety outcomes.
Results: A total of 12 randomized controlled trials (RCTs) were included in the analysis. Diclofenac gel, solution, and patch were all shown to significantly alleviate pain and improve function in patients with knee osteoarthritis. At 1-2 weeks, the diclofenac patch delivered the most pronounced short-term pain relief (SMD: -0.64; 95% CI: -0.90 to -0.39), while the gel and solution demonstrated sustained efficacy over the mid-term (3-6 weeks) and long-term (8-12 weeks). whereas skin-related adverse events, systemic side effects and withdrawal rates remained low across all formulations. The overall quality of evidence was assessed as moderate to high, reinforcing the robustness of the findings.
Conclusions: Topical diclofenac formulations (gel, solution, patch) significantly improve pain and function in knee osteoarthritis compared to placebo. All formulations were well-tolerated, with no significant increase in adverse events. These findings support the use of topical diclofenac for short-term pain relief and functional improvement in KOA patients.
期刊介绍:
BMC Musculoskeletal Disorders is an open access, peer-reviewed journal that considers articles on all aspects of the prevention, diagnosis and management of musculoskeletal disorders, as well as related molecular genetics, pathophysiology, and epidemiology.
The scope of the Journal covers research into rheumatic diseases where the primary focus relates specifically to a component(s) of the musculoskeletal system.